 |
2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5- |
|---|---|
| Trade Name | |
| Orphan Indication | Congenital adrenal hyperplasia |
| USA Market Approval | USA |
| USA Designation Date | 2015-01-15 00:00:00 |
| Sponsor | Neurocrine Biosciences, Inc.;12780 El Camino Real;San Diego, California, 92130 |
